XOM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient buyer. XOM is in a strong uptrend, but it’s extremely overbought (RSI~92) and trading near/through key resistance with limited near-term upside versus many Street price targets. With no Intellectia buy signals today, the higher-probability setup is a pullback/mean reversion rather than an immediate chase entry at 141-142.
Trend is bullish: SMA_5 > SMA_20 > SMA_200 and MACD histogram (+0.995) is positive and expanding, confirming strong momentum. However, RSI_6 at ~92 signals an overbought/late-stage push where short-term downside risk increases. Price (141.66) is above R1 (140.673) and approaching R2 (143.852), implying resistance overhead; first key support is the pivot ~135.53 (then S1 ~130.38). Pattern-based stats provided also skew flat-to-down after the next day (next week/month slightly negative), consistent with an overextended move.
Intellectia Proprietary Trading Signals
increases odds of a near-term pullback.
Latest provided quarter is 2025/Q3: YoY growth was negative—Revenue 83.33B (-5.08% YoY), Net Income 7.55B (-12.33% YoY), EPS 1.76 (-8.81% YoY), and Gross Margin 22.6% (-2.71% YoY). This indicates earnings power was softening versus the prior year, even as the most recent QDEC 2025 quarter delivered a modest EPS beat. Net: operations look strong (record production per Q4 call), but the reported YoY trend in the latest detailed financial snapshot is still down.
Recent trend: price targets were mostly raised into late Jan (Barclays to 140, JPM to 133, BofA to 135 after prior raise to 129), but there were also meaningful cuts (Scotiabank to 128 from 155; Morgan Stanley to 134 from 137) and one downgrade to Sell (Freedom Capital PT 123). Overall stance from major banks skews constructive (several Overweight/Outperform/Buy), but with valuation concerns and targets clustering around 128–142. At the current price (141.66), XOM is already at/above the upper end of many targets, so Wall Street “pros” case is: resilient cash returns + strong production; “cons” case is: valuation premium/limited upside and commodity uncertainty.
Influential/flow checks: hedge funds and insiders are Neutral (no notable recent trend). No recent congress trading data available, and no politician buying/selling was provided in the dataset.
